A report on the blog FiercePharma says that a more stringent warning label for the diabetes drug Byetta spooked some investors when the U.S. Food and Drug Administration issued it in 2008.
At the time, Byetta manufacturers Eli Lilly and Amylin Pharmaceuticals had been in the process of developing a version of the drug that had to be administered only once a week, as opposed to the twice-daily version then on ...
continue reading...